Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.
UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners
Latest from UCSF Helen Diller Family Comprehensive Cancer Center
The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
Advertisement
Advertisement
Trending on CURE
1
Kisqali Plus Aromatase Inhibitor Shows Long-Term Benefit in Early Breast Cancer
2
Tagrisso Plus Chemo Offers Survival benefit in EGFR+ NSCLC
3
Lenvima Combo Fails to Extend Survival in Esophageal Cancer
4
Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia
5
